(VIANEWS) - Renesola Ltd. (SOL), ACM Research (ACMR), Helios Technologies (HLIO) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Renesola Ltd. (SOL)
82.8% sales growth and 3.88% return on equity
ReneSola Ltd, through its subsidiaries, develops, builds, operates, and sells solar power projects in the United States and Europe.
Renesola Ltd.'s sales growth this year is anticipated to be 24.7% and 48% for next year.
Year-on-year quarterly revenue growth declined by 29.2%, now sitting on 67.46M for the twelve trailing months.
Volume
Today's last reported volume for Renesola Ltd. is 492775 which is 65.66% below its average volume of 1435140.
Renesola Ltd.'s sales growth for the next quarter is 82.8%. The company's growth estimates for the present quarter and the next is a negative 0% and negative -72.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.88%.
Volatility
Renesola Ltd.'s last day, last week, and last month's current intraday variation average was 2.61%, 1.59%, and 3.47%, respectively.
Renesola Ltd.'s highest amplitude of average volatility was 6.90% (day), 5.37% (last week), and 6.29% (last month), respectively.
Renesola Ltd.'s Stock Yearly Top and Bottom Value
Renesola Ltd.'s stock is valued at $0.00 at 19:22 EST, below its 52-week low of $5.05.
Renesola Ltd.'s Moving Average
Renesola Ltd.'s value is under its 50-day moving average of $7.61 and below its 200-day moving average of $8.87.2. ACM Research (ACMR)
53.4% sales growth and 15.47% return on equity
ACM Research, Inc., together with its subsidiaries, develops, manufactures, and sells single-wafer wet cleaning equipment for enhancing the manufacturing process and yield for integrated chips worldwide.
ACM Research's sales growth this year is expected to be 49.8% and 41.4% for next year.
Year-on-year quarterly revenue growth grew by 40.6%, now sitting on 210.17M for the twelve trailing months.
Volume
Today's last reported volume for ACM Research is 269145 which is 16.29% below its average volume of 321540.
ACM Research's sales growth for the next quarter is 53.4%. The company's growth estimates for the current quarter and the next is 41.4% and negative 0%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 15.47%.
Volatility
ACM Research's last day, last week, and last month's current intraday variation average was 2.12%, 3.14%, and 2.81%, respectively.
ACM Research's highest amplitude of average volatility was 4.80% (day), 7.54% (last week), and 6.11% (last month), respectively.
ACM Research's Stock Yearly Top and Bottom Value
ACM Research's stock is valued at $78.12 at 19:22 EST, way below its 52-week high of $144.81 and way higher than its 52-week low of $60.84.
ACM Research's Moving Average
ACM Research's worth is way below its 50-day moving average of $102.24 and way below its 200-day moving average of $91.23.3. Helios Technologies (HLIO)
32.4% sales growth and 13.57% return on equity
Helios Technologies, Inc., together with its subsidiaries, develops, manufactures, and sells solutions for the hydraulics and electronics markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
Helios Technologies's sales growth this year is expected to be 58.2% and 6.7% for next year.
Year-on-year quarterly revenue growth grew by 82%, now sitting on 803.12M for the twelve trailing months.
Volume
Today's last reported volume for Helios Technologies is 100340 which is 6.1% below its average volume of 106866.
Helios Technologies's sales growth for the next quarter is 32.4%. The company's growth estimates for the present quarter and the next is 58.5% and 35%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.57%.
Volatility
Helios Technologies's last day, last week, and last month's current intraday variation average was 1.07%, 0.90%, and 1.53%, respectively.
Helios Technologies's highest amplitude of average volatility was 3.91% (day), 3.03% (last week), and 2.97% (last month), respectively.
Helios Technologies's Stock Yearly Top and Bottom Value
Helios Technologies's stock is valued at $101.30 at 19:22 EST, way below its 52-week high of $114.89 and way above its 52-week low of $50.90.
Helios Technologies's Moving Average
Helios Technologies's worth is higher than its 50-day moving average of $95.52 and way higher than its 200-day moving average of $81.10.4. Arthur J. Gallagher & Co. (AJG)
26.6% sales growth and 13.48% return on equity
Arthur J. Gallagher & Co., together with its subsidiaries, provides insurance brokerage, consulting, and third party claims settlement and administration services in the United States, Australia, Bermuda, Canada, the Caribbean, New Zealand, and the United Kingdom.
Arthur J. Gallagher & Co.'s sales growth this year is expected to be 27% and 3.2% for next year.
Year-on-year quarterly revenue growth grew by 22.4%, now sitting on 7.43B for the twelve trailing months.
Volume
Today's last reported volume for Arthur J. Gallagher & Co. is 1680320 which is 74.72% above its average volume of 961691.
Arthur J. Gallagher & Co.'s sales growth for the next quarter is 26.6%. The company's growth estimates for the present quarter and the next is 11.1% and 6.8%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.48%.
Volatility
Arthur J. Gallagher & Co.'s last day, last week, and last month's current intraday variation average was 1.19%, 1.14%, and 0.73%, respectively.
Arthur J. Gallagher & Co.'s highest amplitude of average volatility was 2.76% (day), 2.47% (last week), and 1.82% (last month), respectively.
Arthur J. Gallagher & Co.'s Stock Yearly Top and Bottom Value
Arthur J. Gallagher & Co.'s stock is valued at $162.90 at 19:22 EST, under its 52-week high of $171.18 and way above its 52-week low of $112.92.
Arthur J. Gallagher & Co.'s Moving Average
Arthur J. Gallagher & Co.'s worth is above its 50-day moving average of $162.62 and way above its 200-day moving average of $145.78.5. Bel Fuse (BELFB)
17.9% sales growth and 10.75% return on equity
Bel Fuse Inc. designs, manufactures, markets, and sells products that are used in the networking, telecommunication, high-speed data transmission, commercial aerospace, military, broadcasting, transportation, and consumer electronic industries in the United States, Macao, the United Kingdom, Slovakia, Germany, Switzerland, and internationally.
Bel Fuse's sales growth this year is expected to be 14.4% and 5.9% for next year.
Year-on-year quarterly revenue growth grew by 18.1%, now sitting on 512.48M for the twelve trailing months.
Volume
Today's last reported volume for Bel Fuse is 118846 which is 65.33% above its average volume of 71883.
Bel Fuse's sales growth for the next quarter is 17.9%. The company's growth estimates for the current quarter and the next is 80% and 213%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.75%.
Volatility
Bel Fuse's last day, last week, and last month's current intraday variation average was 3.99%, 2.03%, and 1.47%, respectively.
Bel Fuse's highest amplitude of average volatility was 5.83% (day), 6.76% (last week), and 4.31% (last month), respectively.
Bel Fuse's Stock Yearly Top and Bottom Value
Bel Fuse's stock is valued at $12.52 at 19:22 EST, way under its 52-week high of $23.00 and way above its 52-week low of $10.58.
Bel Fuse's Moving Average
Bel Fuse's worth is below its 50-day moving average of $12.94 and way below its 200-day moving average of $15.15.6. ABIOMED (ABMD)
11.1% sales growth and 11.62% return on equity
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart.
ABIOMED's sales growth this year is expected to be 20.4% and 15.9% for next year.
Year-on-year quarterly revenue growth grew by 18.3%, now sitting on 973.64M for the twelve trailing months.
Volume
Today's last reported volume for ABIOMED is 37621 which is 82.76% below its average volume of 218327.
ABIOMED's sales growth is a negative 0% for the current quarter and 11.1% for the next. The company's growth estimates for the present quarter and the next is a negative 28.1% and negative -9.7%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 11.62%.
Volatility
ABIOMED's last day, last week, and last month's current intraday variation average was 2.97%, 2.61%, and 1.84%, respectively.
ABIOMED's highest amplitude of average volatility was 6.39% (day), 4.84% (last week), and 3.91% (last month), respectively.
ABIOMED's Stock Yearly Top and Bottom Value
ABIOMED's stock is valued at $306.79 at 19:22 EST, way under its 52-week high of $387.40 and way above its 52-week low of $254.41.
ABIOMED's Moving Average
ABIOMED's value is way below its 50-day moving average of $342.12 and under its 200-day moving average of $324.98.7. NICE Ltd (NICE)
7% sales growth and 7.54% return on equity
NICE Ltd.
NICE Ltd's sales growth this year is anticipated to be 11.7% and 10.5% for next year.
Year-on-year quarterly revenue growth grew by 19.7%, now sitting on 1.84B for the twelve trailing months.
Volume
Today's last reported volume for NICE Ltd is 197634 which is 9.74% below its average volume of 218974.
NICE Ltd's sales growth for the next quarter is 7%. The company's growth estimates for the current quarter and the next is 12.1% and 4.3%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.54%.
Volatility
NICE Ltd's last day, last week, and last month's current intraday variation average was 1.56%, 0.77%, and 0.91%, respectively.
NICE Ltd's highest amplitude of average volatility was 3.51% (day), 2.59% (last week), and 2.35% (last month), respectively.
NICE Ltd's Stock Yearly Top and Bottom Value
NICE Ltd's stock is valued at $294.50 at 19:22 EST, below its 52-week high of $319.88 and way above its 52-week low of $211.25.
NICE Ltd's Moving Average
NICE Ltd's worth is above its 50-day moving average of $283.03 and way higher than its 200-day moving average of $256.18.8. Genuine Parts Company (GPC)
6.5% sales growth and 26.77% return on equity
Genuine Parts Company distributes automotive replacement parts, industrial parts and materials, and business products in the United States, Canada, Mexico, Australasia, France, the United Kingdom, Germany, Poland, the Netherlands, and Belgium.
Genuine Parts Company's sales growth this year is expected to be 11.6% and 2.8% for next year.
Year-on-year quarterly revenue growth grew by 25.1%, now sitting on 17.87B for the twelve trailing months.
Volume
Today's last reported volume for Genuine Parts Company is 245040 which is 57.69% below its average volume of 579166.
Genuine Parts Company's sales growth for the next quarter is 6.5%. The company's growth estimates for the current quarter and the next is 0.6% and 0.7%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 26.77%.
Volatility
Genuine Parts Company's last day, last week, and last month's current intraday variation average was 1.36%, 1.42%, and 0.83%, respectively.
Genuine Parts Company's highest amplitude of average volatility was 1.26% (day), 1.38% (last week), and 1.49% (last month), respectively.
Genuine Parts Company's Stock Yearly Top and Bottom Value
Genuine Parts Company's stock is valued at $132.13 at 19:22 EST, below its 52-week high of $137.15 and way above its 52-week low of $93.62.